MediBeacon

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, MediBeacon sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

MediBeacon: 11 sponsored US clinical trials, 2 recruiting.

MediBeacon sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Kidney Injury, with 2 trials.

Top-decile sponsor footprint

MediBeacon ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 1

Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries

NCT07080008
RECRUITING Early Phase 1

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121
NOT YET RECRUITING NA

Evaluation of Protein Loading on Measurement of Renal Reserve

NCT07335614
NOT YET RECRUITING NA

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

NCT07349797
COMPLETED Phase 3

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
COMPLETED Phase 3

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

NCT05425719
COMPLETED Early Phase 1

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

NCT03962998
COMPLETED NA

Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System

NCT03810833
COMPLETED Phase 2

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

NCT02772276
COMPLETED Phase 1

Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers

NCT02098187
COMPLETED Phase 1

Pharmacokinetics of MP-3180 in Healthy Volunteers

NCT02098174

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1
Phase 3 2

Therapeutic Areas

Acute Kidney Injury 2
Glomerular Filtration Rate 1
Retinal Vein Occlusion 1
Kidney Injury 1
Kidney Failure 1
Ureter Injury 1
Retinopathy 1
Macular Degeneration 1
Diabetic Retinopathy 1
Kidney Diseases 1

What is open in the MediBeacon pipeline

2 recruiting of 11 indexed (18% open); 7 completed (64%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Acute Kidney Injury (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

MediBeacon: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

MediBeacon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10.910.91111.1 0%5%10%15%20% Total trials Recruiting share MediBeaconAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityImunonInventisBio Co.
MediBeacon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

MediBeacon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this MediBeacon page

11 registered trials is a research-attention snapshot, not an endorsement of MediBeacon or any single study.

  • 2 of MediBeacon's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Kidney Injury is the condition MediBeacon studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Kidney Injury trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

MediBeacon pipeline card: 11 registered trials from official public datasets.Report a data error.